Search The Medical Knowledge Base

Drug Details

Becodisks 200mcg

• Drug Class Description
  Corticosteroids (steroids).
• Generic Name
  beclometasone dipropionate
• Presentation
  Dry Powder for Inhalation via Diskhaler Device
• Description
  Beclometasone Dipropionate 200micrograms
• Indications
  

  Clinical Indications

  Beclometasone dipropionate provides effective anti-inflammatory action in the lungs, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. It also offers preventive treatment of asthma.

  Becodisks are indicated for the following:

  Adults

  Prophylactic management in:

  Mild asthma (PEF values greater than 80% predicted at baseline with less than 20% variability):

  Patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis.

  Moderate asthma (PEF values 60-80% predicted at baseline with 20-30% variability):

  Patients requiring regular asthma medication and patients with unstable or worsening asthma on other prophylactic therapy or bronchodilator alone.

  Severe asthma (PEF values less than 60% predicted at baseline with greater than 30% variability):

  Patients with severe chronic asthma. On transfer to high dose inhaled beclometasone dipropionate, many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or eliminate their requirement for oral corticosteroids.

• Adult Dosage
  

  Becodisks are for administration by the inhalation route only using a Diskhaler device.

  Patients should be made aware of the prophylactic nature of therapy with inhaled beclometasone dipropionate and that it should be taken regularly everyday even when they are asymptomatic.

  Patients should be given a starting dose of inhaled beclometasone dipropionate which is appropriate for severity of their disease. The dose may then be adjusted until control is achieved and should be titrated to the lowest dose at which effective control of asthma is maintained.

  Adults

  400 microgram twice daily is the usual starting dose. One 400 microgram blister or two 200 micrograms blisters twice daily is the usual maintenance dose. Alternatively, 200 micrograms may be administered three or four times daily.

  Special Patient Groups

  There is no need to adjust the dose in elderly patients or in those with hepatic or renal impairment.

• Child Dosage
  

  100 micrograms two, three or four times a day, according to the response. Alternatively, the usual starting dose of 200 micrograms twice daily may be administered.

• Contra Indications
  

  Hypersensitivity to Becodisks or any of its compnents is a contraindication.

  Special care is necessary in patients with active or quiescent pulmonary tuberculosis.

• Special Precautions
  

  Patients should be instructed in the proper use of the Diskhaler to ensure that the drug reaches the target areas within the lungs. They should be made aware that Becodisks have to be used regularly everyday for optimum benefit. Patients should be made aware of the prophylactic nature of therapy with Becodisks and that they should be used regularly, even when they are asymptomatic.

  Becodisks are not designed to relieve acute asthmatic symptoms for which an inhaled short-acting bronchodilator is required. Patients should be advised to have such rescue medication available.

  Severe asthma requires regular medical assessment including lung function testing as patients are at risk of severe attacks and even death.

  Increasing use of bronchodilators, in particular short-acting inhaled beta₂ agonists to relieve symptoms indicates deterioration of asthma control. If patients find that short acting relief bronchodilator treatment becomes less effective or they need more inhalations than usual, medical attention must be sought.

  In this situation patients should be reassessed and consideration given to the need for increased anti-inflammatory therapy (e.g. Higher doses of inhaled corticosteroids or a course of oral corticosteroids). Severe exacerbations of asthma must be treated in the normal way.

  Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is important therefore that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained.

  It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroid, if possible, to the lowest dose at which effective control of asthma is maintained. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist.

  Prolonged treatment with high doses of inhaled corticosteroids, particularly higher than recommended doses, may result in clinically significant adrenal suppression. Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.

  Lack of response or severe exacerbations of asthma should be treated by increasing the dose of inhaled beclometasone dipropionate and, if necessary, by giving a systemic steroid and/or antibiotic if there is an infection, and by use of beta-agonist therapy.

  For the transfer of patients being treated with oral corticosteroids:

  The transfer of oral steroid-dependent patients to Becodisks and their subsequent management needs special care as recovery from impaired adrenocortical function, caused by prolonged systemic steroid therapy, may take a considerable time.

  Patients who have been treated with systemic steroids for long periods of time or at a high dose may have adrenocortical suppression. With these patients adrenocortical function should be monitored regularly and their dose of systemic steroid reduced cautiously.

  After approximately a week, gradual withdrawal of the systemic steroid is commenced. Decrements in dosages should be appropriate to the level of maintenance systemic steroid, and introduced at not less than weekly intervals. For maintenance doses of prednisolone (or equivalent) of 10mg daily or less, the decrements in dose should not be greater than 1mg per day, at not less than weekly intervals. For maintenance doses of prednisolone in excess of 10mg daily, it may be appropriate to employ cautiously, larger decrements in dose at weekly intervals.

  Some patients feel unwell in a non-specific way during the withdrawal phase despite maintenance or even improvement of the respiratory function. They should be encouraged to persevere with the Diskhaler and withdrawal of systemic steroid continued, unless there are objective signs of adrenal insufficiency.

  Patients weaned off oral steroids whose adrenocortical function is impaired should carry a steroid warning card indicating that they may need supplementary systemic steroid during periods of stress, e.g. Worsening asthma attacks, chest infections, major intercurrent illness, surgery, trauma, etc.

  Replacement of systemic steroid treatment with inhaled therapy sometimes unmasks allergies such as allergic rhinitis or eczema previously controlled by the systemic drug. These allergies should be symptomatically treated with antihistamine and/or topical preparations, including topical steroids.

  Treatment with Becodisks should not be stopped abruptly.

  As with all inhaled corticosteroids, special care is necessary in patients with active or quiescent pulmonary tuberculosis.

• Interactions
  

  No interactions have been reported

• Adverse Drug Reactions
  

  Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (1/10), common (1/100 and <1/10), uncommon (1/1000 and <1/100), rare (1/10,000 and <1/1000), very rare (<1/10,000) including isolated reports and not known (cannot be estimated from the available data). Very common, common and uncommon events were generally determined from clinical trial data. The incidence in placebo and comparator group has not been taken into account in estimation of these frequencies. Rare and very rare events were generally determined from spontaneous data.

  System Organ Class	Adverse Event	Frequency
  Infections & Infestations	Candidiasis of the mouth and throat.	Very Common
  Immune System Disorders	Hypersensitivity reactions with the following manifestations:
  	Rashes, urticaria, pruritis, erythema.	Uncommon
  	Oedema of the eyes, face, lips and throat	Very Rare
  	Respiratory symptoms (dyspnoea and/or bronchospasm)	Very Rare
  	Anaphylactoid/anaphylactic reactions	Very Rare
  Endocrine Disorders	Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, glaucoma	Very Rare
  Psychiatric Disorders	Anxiety, sleep disorders, behavioural changes, including hyperactivity and irritability (predominantly in children)	Very Rare
  	Depression, aggression (predominantly in children)	Not known
  Respiratory, Thoracic & Mediastinal Disorders	Hoarseness/throat irritation	Common
  	Paradoxical bronchospasm	Very Rare

  Candidiasis of the mouth and throat (thrush) occurs in some patients, the incidence of which is increased with doses greater than 400 micrograms beclometasone dipropionate per day. Patients with high blood levels of Candida precipitins, indicating a previous infection, are most likely to develop this complication. Patients may find it helpful to rinse out their mouth with water after using the Diskhaler. Symptomatic candidiasis can be treated with topical anti-fungal therapy whilst still continuing with beclometasone dipropionate treatment.

  Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, glaucoma.

  In some patients inhaled beclometasone dipropionate may cause hoarseness or throat irritation. It may be helpful to rinse out the mouth with water immediately after inhalation.

  As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. This should be treated immediately with a fast-acting inhaled bronchodilator. The beclometasone dipropionate preparation should be discontinued immediately, the patient assessed, and if necessary alternative therapy instituted.